Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stake Lifted by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 19.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,090 shares of the biopharmaceutical company’s stock after purchasing an additional 6,320 shares during the period. Harbor Capital Advisors Inc.’s holdings in Agios Pharmaceuticals were worth $1,737,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its position in shares of Agios Pharmaceuticals by 1.1% during the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after purchasing an additional 63,900 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Agios Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after buying an additional 44,583 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Agios Pharmaceuticals by 5.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,108,613 shares of the biopharmaceutical company’s stock valued at $32,416,000 after acquiring an additional 62,153 shares during the last quarter.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $46.70 on Wednesday. Agios Pharmaceuticals, Inc. has a twelve month low of $20.40 and a twelve month high of $53.28. The firm has a market cap of $2.66 billion, a PE ratio of 4.11, a P/E/G ratio of 0.45 and a beta of 0.75. The firm’s 50 day moving average price is $44.59 and its two-hundred day moving average price is $42.43.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Raymond James reiterated an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Finally, Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $52.33.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.